Introduction {#sec1}
============

The COVID-19 pandemic has brought multiple challenges to the health care system. One of which is the use of QT-prolonging medications with no clear evidence to guide monitoring.[@bib1] While clinicians are familiar with managing patients on QT-prolonging medications, the current situation is different in 3 respects. First, combination therapy of 2 or more proarrhythmic anti-COVID-19 therapies is not uncommon and carry a greater risk of ventricular arrhythmias.[@bib2] ^,^ [@bib3] Second, direct myocardial injury seen with COVID-19 has been shown in basic and clinical studies to increase the susceptibility to QT prolongation.[@bib4] ^,^ [@bib5] Third, the usual practice of performing serial electrocardiograms (ECG) to monitor QT interval is being discouraged due to the risk of viral transmission, which limits the use of previously recommended protocols.[@bib6] As such, it is critical to find an alternative practical and safe method of monitoring the QT interval in these patients. Automated QT interval monitoring through continuous cardiac telemetry (CCT) systems is an appealing alternative due to the minimal contact with patients and its potential ability to detect episodes of transient QT prolongation that could be missed with intermittent QT measurements. We hypothesized that continuous QT monitoring with CCT in patients admitted to critical care units with COVID-19 would detect more episodes of prolonged QT than standard of care.

Materials and methods {#sec2}
=====================

This is a single centre prospective cohort study that included consecutive patients admitted to critical care units affiliated with The Ottawa Hospital (5 units) with confirmed or suspected COVID-19 between April-7^th^-2020 and May-9^th^-2020. The reporting of this study conforms to the STROBE statement.[@bib7] See supplementary table S1 for the STROBE checklist.

On April-28^th^-2020, CCT was implemented in all critical care units receiving COVID-19 patients at The Ottawa Hospital. Patients on CCT were considered the active group (CCT group) and those admitted before CCT were considered controls (control group). Patients were followed until discharge or death. This quality improvement initiative was granted an exemption by the Ottawa Health Science Network Research Ethics Board (OHSN-REB).

CCT group {#sec2.1}
---------

Patients admitted after the implementation of CCT were placed on a cardiac monitor connected electronically to servers at the Arrhythmia Monitoring Centre (AMC) at the University of Ottawa Heart Institute (UOHI). The QT interval monitoring algorithm previously validated by Philips was used.[@bib8] Briefly, this system measures heart-rate corrected QT intervals (QTc) every 30 minutes and displays the results in a table attached to the daily report which was then posted on the electronic medical record (EMR). Bazett's formula is used for heart rate correction.[@bib9] No correction for wide QRS is used. The end of the T wave is determined by a novel algorithm that measures vertical distances from a line connecting the peak of the T wave to a heart-rate adjusted point forward in time. The point with the maximum vertical distance is considered the end of the T wave.[@bib8] A 15-second ECG strip at the time of the maximum QTc measured in 24 hours was attached to the report. Supplementary figure S1 shows an example of such a report. Intermittent ECGs were performed in this group at the discretion of the treating team. For the purpose of this study, the daily maximum QTc provided by the system is called automated QTc (Auto-QTc).

Control group {#sec2.2}
-------------

Patients admitted before the implementation of CCT received the standard of care which consisted of standard bedside telemetry without automated QT measurements and intermittent ECG at the discretion of the treating team. All ECGs were reviewed and the recorded QTc intervals were collected (ECG-QTc).

Data collection {#sec2.3}
---------------

Baseline characteristics including age, gender, comorbidities, QT prolonging medications, QTc recorded on ECG at admission and baseline serum Potassium (K), Calcium (Ca), Magnesium (Mg) and creatinine levels were collected. Patients with at least one positive nasopharyngeal swab were labelled as "confirmed COVID-19" and the rest were labelled as "suspected COVID-19". QT-prolonging anti-microbial therapy for confirmed COVID-19 patients were recorded. EMRs were reviewed for all patients daily to record the QTc, the number of ECGs performed and whether there was death or Torsade de Pointes (TdP). Auto-QTc for the CCT group and ECG-QTc for the control group (when available) were used to report daily maximum QTc.

In days with marked QTc prolongation (Long-QTc), defined as Auto-QTc [\>]{.ul} 500 ms in the CCT-group and ECG-QTc [\>]{.ul} 500 ms in the control group, additional data were collected and included K, Ca and Mg levels, medication adjustment (defined as stopping QT-prolonging medications) and electrolytes supplementation.

Outcomes {#sec2.4}
--------

The pre-specified primary outcome of the study was the proportion of new Long-QTc episodes ([\>]{.ul} 500ms) in each group. Secondary outcomes were episodes of (TdP), the proportion of ECGs performed during the monitoring period and the proportion of Long-QTc episodes that were associated with guidelines' recommended clinical response including medication adjustment or electrolyte supplementation.[@bib1] Progress notes were reviewed to record whether Long-QTc episodes were documented in notes by any physician.

Automated QTc validation {#sec2.5}
------------------------

Two cardiac electrophysiologists (EP) (WA and CJR) blinded to the Auto-QTc over-read a total of 66 consecutive measurements (32% of all Auto-QTc) using a pre-defined protocol. Supplementary figure S2 shows an example of manual QT measurement:-Tangent method to determine the end of T-wave.[@bib10]-Bazett's formula for heart rate correction.[@bib9]-Averaged QTc for 5 consecutive beats in atrial fibrillation.[@bib11]-Adjusted QTc for wide QRS: adjusted QTc = QTc -- \[QRS-120\].[@bib12]

Statistical analysis {#sec2.6}
--------------------

A formal, *a priori* calculation of sample size was carried out before collecting data. We estimated the proportion of Long-QTc to be 30% and 10% in the CCT group and controls, respectively.[@bib13] A sample size of 62 monitoring days in each group was calculated which provides an 80% power to detect a statistically significant difference. Given the uncertainty about the agreement between Auto-QTc and EP-QTc in detecting Long-QTc, we continued collecting data until we had \> 62 monitoring days with EP-QTc measurements.

Continuous data were reported as median (interquartile range) and categorical data as numbers (percentages). Wilcoxon Rank-sum test, Chi Square test and Fisher's exact test were used when appropriate to analyze outcome data. We used mixed-effect multivariate logistic regression modeling to adjust for important confounders. Age was categorized into 2 groups based on previous literature ([\>]{.ul} 68 and \< 68 years).[@bib13] Correlation and agreement between Auto-QTc and EP-QTc were assessed with Pearson's correlation coefficient (r) and Kappa statistics, respectively. Analyses were performed using SAS (version 9.4, The SAS institute, USA) and P values of \< 0.05 were considered statistically significant.

Results {#sec3}
=======

We included 33 patients with 451 monitoring days: 14 patients (206 monitoring days) in the CCT group and 19 patients (245 monitoring days) in the control group.

Patient characteristics {#sec3.1}
-----------------------

[Table 1](#tbl1){ref-type="table"} summarizes patient characteristics. Patients in the control group were older and had more confirmed COVID-19 cases whereas the CCT group had more females. Both groups had comparable comorbidities, baseline electrolytes, baseline QTc on ECG and similar proportions of patients on QT-prolonging medications. Only one patient had QTc \> 500 ms at baseline and was in the CCT group.Table 1Patient characteristicsControl (n= 19)CCT group (n= 14)P valueAge, years67 (57, 74)56 (41, 63)0.036 \*Gender (F)4 (21%)7 (50%)0.136COVID-19 status (Confirmed)8 (42%)1 (7%)0.046 \*PMH:- CAD2 (11%)1 (7%)1.0- AF3 (16%)1(7%)0.62- HTN11 (58%)4 (29%)0.158- CHF3 (16%)3 (21%)1.0- DM8 (42%)2(14%)0.131- Stroke1 (5%)1 (7%)1.0- Depression3 (16%)0 (0%)0.244- CKD1 (5%)1 (7%)1.0- Cirrhosis1 (5%)2 (14%)0.561- COPD2 (11%)3 (21)0.629Creatinine (μmol/L)80 (62, 95)99 (71, 247)0.075K (mmol/L)4.2 (3.7, 4.6)4.2 (3.9, 5)0.289Mg (mmol/L)0.8 (0.8, 0.9)0.9 (0.7, 1.1)0.156Ca (mmol/L)2.1 (2, 2.2)2.1 (1.7, 2.2)0.333On QT-prolonging medications5 (26%)4 (29%)0.886QTc on admission ECG (ms)445 (428, 478)445 (431, 490)0.614Average length of stay, days10 (9, 12)10 (6, 19)0.828In-hospital death6 (32%)4 (29%)1.0[^1]

QT-prolonging anti-microbial therapy for confirmed COVID-19 included Hydroxychloroquine/Azithromycin combination in 3 patients, Hydroxychloroquine alone in 1 patient and Azithromycin alone in 5 patients including the patient in the CCT group. In-hospital mortality was similar between the groups.

Proportions of new marked QTc prolongation (Long-QTc) {#sec3.2}
-----------------------------------------------------

Long-QTc was more frequently detected in the CCT group compared to controls \[69/206 (34%) vs 26/245 11%, P\<0.0001\]. Because important factors were not balanced between the 2 groups, we performed a sensitivity analysis adjusting for these factors (age, gender, COVID status and the number QT-prolonging anti-COVID 19 therapies). Being in the CCT group remained significantly associated with Long-QTc (adjusted odds ratio, 4.10; 95% confidence interval \[CI\], 2.47-6.83; P\<0.0001). Two patients in each group had single episode of Long-QTc and the rest had repeated episodes.

Also, because Auto-QTc did not correct for wide QRS, we performed a second sensitivity analysis excluding patients with wide QRS. CCT group remained significantly associated with more episodes of Long-QTc \[63/199 (31%) vs 10/216 (14%), P\<0.0001\].

Proportions of ECGs performed {#sec3.3}
-----------------------------

ECGs were performed less frequently in the CCT group as compared to controls \[32/206 (16%) vs 78/245 (32%), P\<0.0001\].

Clinical response to new marked QTc prolongation (Long-QTc) {#sec3.4}
-----------------------------------------------------------

Overall, 27/95 (28%) Long-QTc episodes were associated with electrolyte supplementation and none were associated with medication adjustment. Extended electrolytes were checked in 71/95 (75%) of Long-QTc episodes. There was no difference between the 2 groups in checking or supplementing extended electrolytes. In 37 episodes of Long-QTc where Mg level was \< 1 mmol/L, only 17 (46%) had Mg supplementation.[@bib1] ^,^ [@bib6] ^,^ [@bib13] ^,^ [@bib14] [Table 2](#tbl2){ref-type="table"} depicts outcomes associated with each group and [Figures 1](#fig1){ref-type="fig"} A and 1B show clinical response to Long-QTc episodes.Table 2Outcome data per groupControl (n= 245 days)CCT (n= 206 days)P valueEpisodes of marked QTc prolongation of [\>]{.ul} 500 ms (Long-QTc)26/245 (11%)69/206 (34%)\<0.0001\*Daily ECGs performed during monitoring period78/245 (32%)32/206 (16%)\<0.0001\*Episodes of Long-QTc where extended electrolytes were checked\*\*20/26 (77%)51/69 (74%)0.763Any clinical response to Long-QTc\*\*5/26 (19%)22/69 (32%)0.223Physician notes documenting Long-QTc2/26 (8%)0 (0%)0.073Episodes of TdP1 (0.4%)0 (0%)1.0[^2][^3]Figure 1Clinical response to marked prolongation in QTc (A) and Magnesium (Mg) replacement during episodes of marked QTc prolongation (B)

One episode of TdP was observed in the control group and none in the CCT group. ECG-QTc was 577 ms after the TdP episode and 565 ms the day prior. Extended electrolytes were checked and supplemented in both days, but no medication adjustment was made (the patient was on Propofol which was not stopped).

Automated QTc (Auto-QTc) Validation {#sec3.5}
-----------------------------------

There was strong correlation between Auto-QTc and EP-QTc (r=0.8, P\<0.0001) and excellent agreement in detecting Long-QTc (Kappa=0.8, P\<0.008). The sensitivity of Auto-QTc in detecting any episode of EP-QTc [\>]{.ul} 500 ms was 100% and the specificity was 84%. The difference between Auto-QTc and EP-QTc was assessed in 66 pairs and showed that Auto-QTc over-estimated QTc by a median of 3 ms (IQR 0-40 ms). [Figure 2](#fig2){ref-type="fig"} A shows the distribution of this difference and [figure 2](#fig2){ref-type="fig"}B is a dot plot diagram of all 66 paired measurements. Because Auto-QTc over-estimated QTc when compared to EP-QTc, we performed a sensitivity analysis excluding Auto-QTc that were not validated by EP (i.e. comparing EP-QTc vs ECG-QTc). The difference in the proportion of L-QTc between the 2 groups remained significant \[23/66 (35%) vs 26/245 (11%), P\<0.0001\].Figure 2Box plot of the difference between automated QTc measurement (Auto-QTc) and manual QTc measurement by an electrophysiologist (EP-QTc) (A) and dot plot diagram of Auto-QTc and EP-QTc measurements (B)

Discussion {#sec4}
==========

Our study showed that continuous QT interval monitoring detects more episodes of prolonged QTc than standard of care. Also, the institution of CCT was associated with a reduction in the number of ECGs being performed, which is likely due to the availability of continuous QT monitoring for serial ECGs, notwithstanding potential residual confounding. Our findings have important clinical implications for COVID-19 and, potentially, non-COVID-19 patients who are treated with medications that are either known to be proarrhythmic or with uncharacterized risk profile.

QT interval monitoring is the first step in the effort to mitigate the risk of ventricular arrhythmias in hospitalized patients.[@bib6] While there are no clear recommendations to guide choosing the best strategy of QT monitoring, performing serial ECGs is the most common practice used.[@bib6] ^,^ [@bib13] This strategy, however, has several limitations. First, it neglects the dynamic nature of the QT interval.[@bib15] Sympathetic tone, hormones, medications and electrolytes influence the QT interval and are highly variable during the course of the day of any hospitalized patient.[@bib16] ^,^ [@bib17] This explains why intermittent QT monitoring could miss periods of prolonged QT interval even if done daily. Second, the best time to assess QT interval after administration of any QT-prolonging medications is often unknown as the degree and timing of QT prolongation varies depending on the pharmacokinetics of the medication used, route of administration and renal and hepatic function of the patient.[@bib6] This is particularly challenging when higher doses or new combination of known proarrhythmic medications are used such as the use of high dose Hydroxychloroquine and the combination of Azithromycin/Hydroxychloroquine during the current COVID-19 pandemic.[@bib3] ^,^ [@bib18] Last, performing serial ECGs mandates additional contact with infected patients which is particularly disadvantageous in patients with highly infectious disease like COVID-19.

While continuous QT monitoring is appealing, one needs to be cautious not to rely on the automated QTc readings provided by the monitoring system without validation. Indeed, our study showed that the automated QTc systematically over-estimates manual QTc measurement by electrophysiologists. This is likely the result of using different methods to identify the end of the T wave and the failure of automated QTc measurements to adjust for wide QRS. However, this should not preclude using automated QTc measurements in daily practice as it could be used as a "screening" tool to identify QTc measurements that need to be verified by physicians. This is supported by the high sensitivity of automated QTc in detecting any episode of QTc [\>]{.ul} 500 ms. Moreover, many experts recommend initiating electrolyte supplementation and stopping QT-prolonging medication at a threshold lower than 500 ms.[@bib1] ^,^ [@bib12] As such, most episodes detected by the automated QTc measurement in our study likely fall in the category of episodes that deserve intervention.

Regardless of the strategy and method of QT interval monitoring used, one can only expect improvement in clinical outcomes if episodes of prolonged QTc are treated properly. Despite numerous recent publications recommending preventative measures in patients with prolonged QTc, most episodes with marked QTc prolongation in our study were not treated with these measures.[@bib1] ^,^ [@bib12] ^,^ [@bib19] ^,^ [@bib20] This suggests that simply reporting the prolonged QTc is not enough to alert the primary team. Akin to the automated infectious disease consultation for Staphylococcus bacteremia and the automated notification of critical lab values used in many institutions, efforts to establish clinical pathways to better manage episodes of prolonged QTc are necessary.[@bib21] ^,^ [@bib22] Jain et al[@bib23] developed a protocol whereby ECGs from COVID-19 patients were tagged for expedited review. An automated phone consult by the electrophysiology service was then initiated for any patient with prolonged QTc. This led to identifying significant numbers of prolonged QTc episodes and instituting relevant interventions. Future studies will need to examine whether these interventions lead to more adherence to recommended therapies and, more importantly, improvement in clinical outcomes.

Most patients in our study had more than one episode of marked QTc prolongation during their admission. This is likely because these patients have factors such as age, gender, ethnicity and/or genetic variants that predispose them to prolonged QTc every time they are re-exposed to a risk factor.[@bib24], [@bib25], [@bib26], [@bib27] Only one of these episodes was associated with TdP which is in line with previous reports.[@bib3] ^,^ [@bib28] ^,^ [@bib29] It is critical that this is not used to lighten our concerns about QTc prolongation. While there are multiple risk factors for TdP, prolonged QTc is the single most important modifiable risk factor than can be treated effectively with low-risk interventions. As such, we should continue every effort to find the best strategy of preventing, detecting and treating episodes of QTc prolongation.

Our study has several limitations. First, this was not a randomized clinical trial. However, differences in the baseline characteristics of and disease severity are unlikely to explain our results and that was supported by our adjusted analysis. Second, our results are specific to the QT interval monitoring algorithm by Philips which might not be generalizable to other systems. The lack of QTc correction for wide QRS is an important limitation of this system. However, the difference between the 2 groups remained significant after excluding patients with wide QRS. As discussed above, a strategy of using the automated system as a screening tool for marked QTc prolongation is practical and safe. Similarly, our study only included patients admitted to critical care units. These patients, however, typically receive more monitoring than patients admitted to non-critical care units and, as such, this is unlikely to bias the result away from the null. Last, the small number of ECGs performed in the CCT group prevent any meaningful analysis to correlate Auto-QTc with ECG-QTc. However, this is not necessary as manual QTc measurement from telemetry strips is a well accepted method that is endorsed by all relevant organizations and is been used in studies examining hospital acquired QTc prolongation.[@bib6] ^,^ [@bib13] ^,^ [@bib30]

Conclusion: {#sec5}
===========

We reported an improvement in detecting episodes of marked QTc prolongation with the use of continuous QT monitoring in a cohort of patients with suspected or confirmed COVID-19. Screening QTc intervals with an automated QTc algorithm is feasible. Efforts to improve adherence to recommended therapies of prolonged QTc episodes is needed.
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[^1]: \* Significant P value. Data presented as median (interquartile range) or number (percentage). CCT: continuous cardiac telemetry, PMH: past medical history, CAD: coronary artery disease, AF: atrial fibrillation, HTN: Hypertension, CHF: congestive heart failure, DM: diabetes mellitus, CKD: chronic kidney disease, COPD: chronic obstructive pulmonary disease, K: Potassium, Mg: Magnesium, Ca: Calcium

[^2]: \* Significant P value.

[^3]: \*\* These were only assessed in episodes of Long-QTc. CCT: continuous cardiac telemetry, TdP: Torsade de Pointes.
